Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Albo is right to want to make things in Australia. He’ll just need a bit more cash

It’s a new era of geopolitical competition out there, where old certainties of ‘free trade’ are ending. Australia needs to pivot — will Albanese’s policy be enough?

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

Investors Business Daily

Shark Tank's Mark Cuban speaks out on weight-loss drugs

Shark Tank's Mark Cuban speaks out on weight-loss drugs

A conversation TheStreet engaged in with Cuban about weight-loss drugs shifted from Novo Nordisk's Ozempic to something new from Eli Lilly.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Best Mega-Cap Stocks for Dividend Investors

Discover the compelling stories behind three mega-cap dividend stocks that have caught the attention of analysts and investors alike.

Ozempic success story: 'Weight-loss drugs, costs and my health'

Ozempic is pricey, but a great health insurance plan paved the way for a software professional to experience dramatic results.

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin

The company leads the weight-loss drugs market with its blockbuster, Wegovy. But next-generation drugs are coming.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Costco enters a controversial industry with its latest move

Costco enters a controversial industry with its latest move

The retail giant is expanding one of its beloved programs to include a growing trend.

Ozempic, weight-loss drugs force a change of focus on health

Ozempic, weight-loss drugs force a change of focus on health

The effectiveness of weight-loss drugs mean people who take them have more fitness challenges to confront.

Ozempic, weight-loss drugs rise and the fitness industry reacts

Ozempic, weight-loss drugs rise and the fitness industry reacts

The increasing popularity of GLP-1 medications such as Ozempic triggers some changes.

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

The Guardian - UK

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Investors Business Daily

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

Viking Surges After Weight-Loss Pill — A Rival To Novo, Lilly — Beats Expectations In Just 28 Days

Viking Surges After Weight-Loss Pill — A Rival To Novo, Lilly — Beats Expectations In Just 28 Days

Viking stock gapped up Tuesday after the biotech company's oral weight-loss drug beat expectations in a 28-day study.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.

Novo Nordisk and Eli Lilly stocks dipped Thursday after Medicare said it could pay for weight-loss drugs for some members.

Mark Cuban shares thoughts on Ozempic and his drug company

The Shark Tank billionaire has a question for Novo Nordisk and TheStreet seeks an answer.

Investors Business Daily

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss

Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.

International Business Times

Nvidia, Novo Nordisk Forge Path To Medical Breakthroughs With AI Supercomputer Gefion

Nvidia and Novo Nordisk's joint venture, Gefion, represents a groundbreaking endeavor in medical research, leveraging AI technology.

Get all your
news in one place.

100’s of premium titles.
One news app.

Novo Nordisk Foundation Expanding Grants Internationally

Novo Nordisk Foundation expands global grant allocation to drive research and innovation beyond Denmark, fostering collaborations and excellence worldwide.

Investors Business Daily

Eli Lilly Taps Amazon's Pharmacy To Deliver Meds, Including Weight-Loss Drug Zepbound

Eli Lilly said Wednesday it tapped Amazon.com's pharmacy division to deliver some of its prescription meds, including its weight-loss drug.

As Ozempic surges in popularity, a controversy arises

Novo Nordisk stock soars. One Harvard Medical School doctor explains his concerns.

FDA Approves Novo Nordisk's Wegovy For Lowering Heart Risks

FDA approves Novo Nordisk's Wegovy for reducing heart risks in weight management. Novo Nordisk's innovative solution targets weight management and heart risks.

FDA approves Wegovy for lowering heart attack and stroke risk in overweight patients

The popular weight-loss drug can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, the FDA said.

International Business Times

US FDA Approves Wegovy To Cut Risk Of Heart Problems

The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage.

Wegovy Approved To Reduce Cardiovascular Risk In Overweight Patients

FDA approves Wegovy label change to reduce cardiovascular risk in overweight patients, a significant advancement in obesity treatment with potential implic...

1 … 6 7 8 9

People

Anthony Albanese

Kritika SarmahHer

Todd Rosenbluth

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Harvard University

SP Global Market Intelligence

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Alzheimer Disease

Places

243,891 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play